Advanced Techniques in Biology & Medicine

Advanced Techniques in Biology & Medicine
Open Access

ISSN: 2379-1764

+44 1223 790975

Wei Wei

Wei Wei
Research Associate, Cancer Center, Massachusetts General Hospital, Harvard Medical School,


He have been working for the past 6 years on the development of novel, personalized therapeutic regimes to improve the prognosis of ovarian cancer, a deadly disease claiming approximately 160,000 deaths each year in the world. By participating in several NIH or US-DoD funded projects, my researches focus on the identification of genomic abnormalities and aberrant gene expression signatures in ovarian cancer through high-throughput technologies with a special emphasis on the biological and clinical relevance on the identified biomarkers. He have a broad background in molecular biology and cancer biology as well as the expertise on independent experimental design and motivation necessary to successfully carry out the proposed work. During my post-doctoral training at MGH, he have expanded his capabilities into high-throughput technologies including microarray or next-generation sequencing based genomic, epigenomic and transcriptomic profiling, and related bioinformatics for data analyses and integration. Through systematic analyses of carefully collected and annotated genomic data from ovarian cancer patients and subsequent validation in molecular biology, he have identified and characterized aberrantly activated FGF18/FGFR4 axis and TGF-β signaling in subsets of ovarian cancer patients and linked them with poor overall survival and decreased optimal cytoreductive surgery. Recently, he have been awarded a 2-year grant as principle investigator to investigate the expression profile of non-coding regulatory microRNA in early-stage ovarian cancer through Ovarian Cancer Research Fund, which is the oldest and largest charity in the US funding ovarian cancer research.

Research Interest

His main research interesting is high-throughput genomic technology based identification of novel biomarkers for early-diagnosis and personalized therapeutic intervention, as well as the characterization of the biological impact of identified biomarker on the biology of tumor cells and tumor microenvironment. • Genomic profiling, data analysis and biomarker identification • Tumor biology (proliferation, metastasis, adhesion, apoptosis, autophagy, signal transduction and gene regulation) • Tumor microenvironment (angiogenesis, tumor-associated fibroblasts, tumor-associated macrophages) • Cytotoxic and targeted chemotherapy (intrinsic and adaptive resistance, DNA repair, BRCAness) • Gynecologic cancers (especially ovarian cancer) and esophageal cancer